The Biomedical Research Institute of Southern California
Nonprofit profile at a glance
- EIN
- 452210161
- IRS 990-EZ coverage
- 2021–2024
- Forms available
- Form 990 2023, Form 990-EZ 2024, Form 990-N 2013
- Location
- Oceanside, CA, USA
- Phone
- 8887235830
- Rating
- 42
- Verdict
- MIXED
- Rating confidence
- Moderate
- Sector
- Biomedicine, Bioengineering Research
Reported finances
- Revenue
- $141,627
- Expenses
- $136,871
- Assets
- $55,641
- Liabilities
- $46,031
Source: IRS Form 990-EZ. Selected filing: tax year 2024. Amounts in USD.
Leadership & pay
5 people listed
Executive titles in this filing
- SALLY SARAWAR (PRESIDENT AND CEO)
People named in this filing
- PETER DIAS (CFO)
- CRAIG JACKSON (DIRECTOR)
- LEMAN YEL (DIRECTOR)
Selected names, not a complete roster or a statement of current roles. Open leadership details for the complete filed list.
Source: IRS Form 990-EZ. Selected filing: tax year 2024. Names and roles reflect this filing, not necessarily current officeholders.
Overview
Mission
The mission of this organization is to conduct basic research to advance our understanding of the fundamental mechanisms of normal biological processes and how those differ in disease states. Our goal is to identify new ways to diagnose, prevent or treat human disease. Our areas of interest include cancer, diabetes, osteoarthritis, asthma and other respiratory diseases, transplantation, chronic fatigue syndrome and infectious diseases.
What it reported doing in 2024
Viral immunologythe objective of this program is to conduct research into the mechanisms by which the immune system protects against viral infections. This research will help us to develop better vaccines and therapeutic agents for viral infections. This program includes pre-clinical work on a novel universal influenza vaccine, the mechanism by which it protects against multiple strains of influenza and whether the vaccine protects against secondary bacterial infections often increase mortality from influenza. We are also investigating novel vaccine adjuvants and why immune responses to certain vaccines wane over time. Diabetesthe goal of this program is to identify unique events and molecular pathways that can trigger the autoreactive t cells to cause destruction of the pancreatic islets in type 1 diabetes. The role of exosomes and novel self-antigens encoded by endogenous retroviruses is a major focus of this study. Our funding for these programs lapsed in 2022 and we had to sublease some of our office and laboratory space, to a company developing novel cancer drugs. We were able to continue working on our programs using existing resources, while attempting to secure new grant funding. We were successful in obtaining funding; however, the new grant funding did not start until march 2023.
Operating model
- Revenue model
- Other-operating. 85% of the money available for current operations came from other operating revenue.
- Distribution model
- No current program activity. The filing reports no program spending for the current year.
The verdict
MIXED - The filed numbers largely add up. A relatively small share of available resources goes toward mission work and a relatively small share of total spending goes to programs.
Rating breakdown
- Financial Efficiency: 0
- Transparency & Controls: 100
- Sustainability: 32
- Growth: 0
Detailed rating inputs
Financial Efficiency
- Mission deployment rate: 0%; rating input score 0
- Program expense ratio: 0%; rating input score 0
Transparency & Controls
- Consistency checks: 100%; rating input score 100; 52nd percentile among comparable filings
- Major donor itemization: Yes; rating input score 100
Sustainability
- Operating margin: 3.4%; rating input score 43; 43rd percentile among comparable filings
- Total-asset coverage ratio: 0.41; rating input score 32; 32nd percentile among comparable filings
- Liabilities to assets ratio: 0.83; rating input score 6; 6th percentile among comparable filings
- Officer compensation ratio: 21.5%; rating input score 15; 15th percentile among comparable filings
Growth
- Program expense growth: -85.7% per year; rating input score 0; 2nd percentile among comparable filings
- Revenue growth: -16.4% per year; rating input score 0; 3rd percentile among comparable filings
- Asset growth: -4.3% per year; rating input score 0; 17th percentile among comparable filings
Details
- Where the money goes: 0% of revenue deployed · 0% of spending went to programs
- Governance: Filed governance answers
- Accomplishments: 1 filed program accomplishment
- Leadership: top reported pay $0 · 5 people listed
- Consistency: 8 of 8 current checks pass
- Schedules: 4 filed schedules
- Filing history: 3 filing years from 2021 to 2024
- Contacts: How to reach this organization
- Money network: 6 filed money-flow records
- Grant readiness: Federal tax and exclusion status, award history, and grant-maker relationships.
- People: Everyone the filings name, and which of them the filings identify by more than a name.
Key Signals
Signals prioritize questions for review. They are not findings of misconduct.
- High — Financial Efficiency: Mission deployment rate scored 0/100.
- High — Financial Efficiency: Program expense ratio scored 0/100.
- High — Growth: Program expense growth scored 0/100.
- High — Growth: Revenue growth scored 0/100.
- Moderate — Sustainability: Operating margin scored 43/100.
- High — Growth: Asset growth scored 0/100.
- Moderate — Sustainability: Total-asset coverage ratio scored 32/100.
- High — Sustainability: Liabilities to assets ratio scored 6/100.
- High — Sustainability: Officer compensation ratio scored 15/100.